

CLAIMS:

What I claim as my invention is:

1. A method to test for the ability of a stealth virus isolated from a patient to induce the production of magnetic and/or paramagnetic material in cells, comprising i) culturing blood and/or tissue samples from a stealth virus infected patient in a manner that will allow for stealth virus induced production of pigmented intracellular and/or extra-cellular material, ii) determining microscopically whether freely floating pigmented material will move either towards or away from an approaching magnet, and iii) concluding that magnetic and/or paramagnetic material is inducible by the stealth virus if the pigmented material moves in response to the approaching magnet.
2. The method of claim 1 in which the detection of magnetic and/or paramagnetic material in a stealth virus culture is achieved by using an alternative detection method.
3. A method of testing the ability of a magnetic field to cause damage to stealth virus infected cells comprising i) culturing blood and/or tissue samples from a stealth virus infected patient in a manner that will allow for the development of a stealth virus induced cytopathic effect ii) exposing the culture to a magnetic field

and iii) examining the cultured cells microscopically for morphological and/or functional signs of cell damage in response to being exposed to the magnetic field.

4. A method of treating a stealth virus infected patient based on exposing known or suspected virus infected cells within the patient to a magnetic field that can be shown to induce cellular damage to stealth virus infected cells in tissue culture, and not to cause similar morphological and/or functional signs of cell damage to corresponding normal uninfected cells.

5. The method of claim 4 in which the stealth virus infected cells are causing diseases in animals.

6. The method of claim 4 in which stealth virus infected cells in the patient are present within a cancer.

7. The method of claim 6 in which the therapy is applied to a known cancer mass present within the individual to be treated.

8. The method of claim 6 in which the therapy is applied to an area of the body in which one might expect or suspect microscopic deposits of cancer cells to be present.

9. The method of claim 4 in which the stealth virus infected cells are causing a non-malignant illness in a patient.

10. A method of treating a stealth virus infected patient based on exposing stealth virus infected bacteria within the patient to a magnetic field that is capable of killing cultured bacteria infected with the stealth virus derived from the patient.

11. The method of claim 10 in which the stealth virus infected bacteria are causing a bacterial illness.

12. A method of destroying all or some of any suspected stealth virus infected cells in a blood sample, or in a blood unit to be used for transfusion, or in other biological samples, comprising the use of a magnetic field administered to the sample in such a manner that has previously been shown to cause the destruction of at least a proportion of the stealth virus infected cells in other blood samples and/or blood units that were known to be infected with a stealth virus.

13. A method of claim 12 in which the stealth virus infected cells are suspected of being present in a tissue graft to be used for transplantation.

14. A method of destroying all or some of any suspected stealth virus infected bacteria in an environmental sample, comprising the use of a magnetic field administered to the sample in such a way that it can be shown to cause the

destruction of at least a proportion of the stealth virus infected bacteria in a comparable environmental sample that was known to be infected with a stealth virus.

0